Study S002241

EFFICACY AND SAFETY OF GZR18 INJECTED EVERY 2 WEEKS (Q2W) IN PARTICIPANTS WITHOUT TYPE 2 DIABETES, WHO HAVE OBESITY OR ARE OVERWEIGHT: A RANDOMIZED, TIRZEPATIDE- AND PLACEBO-CONTROLLED STUDY

ClinicalTrials.gov record

Registration

Registration: NCT06737042
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 326
Start: 2025-02-24
Primary completion: 2026-02-27
Lead sponsor: Gan and Lee Pharmaceuticals, USA
Conditions: Obesity and Overweight
Interventions: DRUG:GZR18; DRUG:Tirzepatide
Results posted: FALSE

Registered primary outcomes

Primary Objective [36 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.